OraVerse (Phentolamine Mesylate) Injection, 0.4 mg/1.7mL, packaged in a box of 10 cartridges of 0.4mg/1.7mL each, Rx only, Distributed by Septodont, Inc., Louisville, CO 80027, Made in Canada by Novocol Pharmaceutical of Canada, Inc., NDC 0362-0101-10
Published May 16, 2018 · Recall initiated: April 13, 2018
Summary
FDA records drug Class III recall D-0828-2018, published May 16, 2018 and initiated April 13, 2018. Recalling firm: Septodont Inc.; Status: Terminated; Reported quantity: 8509 boxes; Lot: Lot #'s D01894E and D01894G. Class III means the product is not likely to cause adverse health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Impurities/Degradation: This recall has been initiated due to an out of specification (OOS) result that was obtained for related substance (Phentolamide), a known degradation product impurity at the 15 month stability test point.
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email if ORAVERSE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- ORAVERSE
- Manufacturer
- Septodont Inc.
- Distributor
- USA, Italy and France
- Lot
- Lot #'s D01894E and D01894G
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAOraVerse, (Phentolamine Mesylate) Injection, 0.4 mg/1.7mL, packaged in a carton containing 10 cartridges, 0.4December 24, 2025
- FDAMacroaggregated albumin (MAA) kit (for the preparation of Tc99m MAA), Aggregated and non-Aggregated HumanMay 16, 2018
- FDAMinivelle (estradiol transdermal system) 0.1 mg/day, 1 System per pouch (NDC 68968-6610-1), packaged in 8May 16, 2018
- FDALupron Depot 22.5 mg 3 month Kit NDC 00074-3346-03 84 days supplyMay 16, 2018
- FDAMinivelle (estradiol transdermal system) 0.0375 mg/day, 1 System per pouch (NDC 68968-6637-1), packaged in 8May 16, 2018
- FDAOPDIVO 40 mg/4 mL SDV NDC 00003-3772-11 28 days supplyMay 16, 2018
Questions about this recall
Was OraVerse (Phentolamine Mesylate) Injection, 0.4 mg/1.7mL, packaged in a box of 10 cartridges of 0.4mg/1.7mL each, Rx only, Distributed by Septodont, Inc., Louisville, CO 80027, Made in Canada by Novocol Pharmaceutical of Canada, Inc., NDC 0362-0101-10 recalled?
Yes. FDA published recall D-0828-2018 on May 16, 2018. Reported hazard: Failed Impurities/Degradation: This recall has been initiated due to an out of specification (OOS) result that was obtained for related substance (Phentolamide), a known degradation product impurity at the 15 month stability test point.
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: ORAVERSE.